Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYT-300 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LYT-300 | DRUG | A prodrug of allopregnanolone, a small molecule drug |
| Placebo | OTHER | Placebo for LYT-300 |
LYT-300 is an investigational small molecule being studied in healthy volunteers. It is currently in clinical development, with a completed Phase 1/Phase 2 trial. The drug has not been approved by regulatory authorities and remains under investigation.
LYT-300 is being developed by PureTech Health plc, a biopharmaceutical company. PureTech Health plc is publicly traded under the ticker symbol PRTC. The company is conducting clinical research on this investigational small molecule.
LYT-300 is in Phase 2 clinical development. A Phase 1/Phase 2 trial has been completed, and the drug remains investigational. It is not approved for any use and is still being studied in clinical trials.
LYT-300 has one completed clinical trial, identified as NCT05129865, titled 'LYT-300 in Healthy Volunteers.' This Phase 1/Phase 2 study enrolled 186 participants and was an uncontrolled, non-randomized, non-double-blind trial. No active trials are currently listed.
LYT-300 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 1/Phase 2 trial in healthy volunteers does not constitute approval, and the drug remains under study.